309th Hospital of Chinese People's Liberation Army
11
0
0
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
45%
5 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT
Role: collaborator
Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma
Role: collaborator
A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC
Role: collaborator
Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation
Role: collaborator
Intracranial Artery Stenosis Magnetic Resonance Imaging: Aetiology and Progression
Role: collaborator
CRC Post-surgical Assessment and Recurrence Monitoring
Role: collaborator
Clinical Study of Microchimerism and cfDNA as Biomarkers for Acute Rejection After Organ Transplantation
Role: collaborator
A Hospital Based Survey on Lung Cancer Related-pain in Northern China
Role: collaborator
The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation
Role: collaborator
Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Role: collaborator
Perfluorocarbon (PFC) Inhalation Treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome
Role: collaborator
All 11 trials loaded